#United States #Abbott #Abbott Park #cancer screening #Exact Sciences

Abbott's Strategic Acquisition of Exact Sciences

On March 23, 2026, Abbott, a global healthcare leader, proudly announced the successful completion of its acquisition of Exact Sciences. This pivotal move establishes Abbott as a dominant player in the cancer screening and diagnostics sectors, which are witnessing rapid growth in light of increasing global cancer rates.

The Vision Behind the Acquisition

The acquisition aligns perfectly with Abbott's mission to enhance healthcare accessibility and empower individuals with greater control over their health. According to Robert B. Ford, the chairman and CEO of Abbott, the integration of Exact Sciences will harness Abbott's global resources and operational excellence to make crucial tools for early cancer detection widely available. The collaboration aims to reshape cancer care, leveraging the expertise and innovative solutions that Exact Sciences brings to the table.

With Exact Sciences now functioning as a wholly owned subsidiary, the acquisition signifies the cessation of Exact Sciences' trading on the Nasdaq stock market as of March 20, 2026. This strategic alignment is anticipated to accelerate Abbott's capabilities in diagnosing and treating cancer, at a time when such innovations are critically needed.

Expanding Abbott's Diagnostic Portfolio

Abbott's acquisition significantly enhances its already robust portfolio of diagnostic tools aimed at the early detection and personalized treatment of cancer. Among the industry-leading products now available to Abbott are:

• - Cologuard®: A groundbreaking non-invasive colorectal cancer screening test that allows for early diagnosis and saves lives.
• - Oncotype DX®: This test supports personalized treatment decisions for breast cancer patients, ensuring tailored approaches for optimal outcomes.
• - Oncodetect®: A molecular residual disease test that aids in identifying cancer recurrence and guiding the necessary follow-up care.
• - Cancerguard®: A multi-cancer early detection blood test designed to identify various types of cancer early on.

These offerings position Abbott to capture a significant share of the estimated $60 billion U.S. cancer screening and precision oncology diagnostics market.

Looking to the Future

With a commitment to innovation, Abbott is not only steadying its grip on existing healthcare solutions but also poised to introduce next-generation cancer diagnostics. These advancements will enable earlier detection of cancer, more informed treatment decisions, and consistent monitoring, ultimately aiding patients in maintaining their health more effectively.

About Abbott

Abbott is devoted to helping individuals lead fuller lives at every stage. The company’s extensive portfolio encompasses a wide range of technologies and products in diagnostics, medical devices, nutritional products, and branded generic medicines. With approximately 122,000 employees across 160 countries, Abbott is uniquely positioned to deliver impactful healthcare solutions and reach a broader audience.

In conclusion, Abbott's acquisition of Exact Sciences is seen as a landmark decision, reinforcing the company's commitment to enhancing cancer care through innovative diagnostics. This strategic integration stands to benefit millions of patients, paving the way for a healthier future across the globe.

---